Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1421

1.

Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells.

Chen LS, Keating MJ, Wierda WG, Gandhi V.

Leuk Lymphoma. 2019 Jun 4:1-4. doi: 10.1080/10428194.2019.1622098. [Epub ahead of print] No abstract available.

PMID:
31161836
2.

Inferring clonal heterogeneity in cancer using SNP arrays and whole genome sequencing.

Zucker MR, Abruzzo LV, Herling CD, Barron LL, Keating MJ, Abrams ZB, Heerema N, Coombes KR.

Bioinformatics. 2019 Jun 2. pii: btz243. doi: 10.1093/bioinformatics/btz243. [Epub ahead of print] No abstract available.

PMID:
31161200
3.

Growth dynamics in naturally progressing chronic lymphocytic leukaemia.

Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, Neuberg D, Kipps TJ, Nowak MA, Getz G, Wu CJ.

Nature. 2019 May 29. doi: 10.1038/s41586-019-1252-x. [Epub ahead of print]

PMID:
31142838
4.

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W.

N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.

PMID:
31141631
5.

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.

Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A.

Blood Adv. 2019 May 14;3(9):1533-1539. doi: 10.1182/bloodadvances.2019031336.

6.

PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.

Cervantes-Gomez F, Stellrecht CM, Ayres ML, Keating MJ, Wierda WG, Gandhi V.

Oncotarget. 2019 Apr 19;10(29):2793-2809. doi: 10.18632/oncotarget.26876. eCollection 2019 Apr 19.

7.

Matrix crosslinking enhances macrophage adhesion, migration, and inflammatory activation.

Hsieh JY, Keating MT, Smith TD, Meli VS, Botvinick EL, Liu WF.

APL Bioeng. 2019 Mar 27;3(1):016103. doi: 10.1063/1.5067301. eCollection 2019 Mar.

8.

Comparison of Minimally Invasive Tissue Sampling With Conventional Autopsy to Detect Pulmonary Pathology Among Respiratory Deaths in a Resource-Limited Setting.

Roberts DJ, Njuguna HN, Fields B, Fligner CL, Zaki SR, Keating MK, Rogena E, Walong E, Gachii AK, Maleche-Obimbo E, Irimu G, Mathaiya J, Orata N, Lopokoiyit R, Michuki J, Emukule GO, Onyango CO, Gikunju S, Owuor C, Muturi PK, Bunei M, Widdowson MA, Mott JA, Chaves SS.

Am J Clin Pathol. 2019 Jun 5;152(1):36-49. doi: 10.1093/ajcp/aqz016.

PMID:
31006817
9.

Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies.

Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A.

J Geriatr Oncol. 2019 Apr 17. pii: S1879-4068(19)30033-5. doi: 10.1016/j.jgo.2019.04.002. [Epub ahead of print]

PMID:
31005650
10.

Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.

Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG.

Br J Haematol. 2019 Jun;185(5):852-864. doi: 10.1111/bjh.15877. Epub 2019 Mar 28.

PMID:
30924136
11.

Age-dependent overall survival benefit of androgen deprivation therapy for metastatic prostate cancer.

Keating MJ, Giscombe L, Tannous T, Reddy N, Mukkamalla SKR, DeSouza A, Rathore R.

J Oncol Pharm Pract. 2019 Mar 16:1078155219835597. doi: 10.1177/1078155219835597. [Epub ahead of print]

PMID:
30880568
12.

An integrative systems genetic analysis of mammalian lipid metabolism.

Parker BL, Calkin AC, Seldin MM, Keating MF, Tarling EJ, Yang P, Moody SC, Liu Y, Zerenturk EJ, Needham EJ, Miller ML, Clifford BL, Morand P, Watt MJ, Meex RCR, Peng KY, Lee R, Jayawardana K, Pan C, Mellett NA, Weir JM, Lazarus R, Lusis AJ, Meikle PJ, James DE, de Aguiar Vallim TQ, Drew BG.

Nature. 2019 Mar;567(7747):187-193. doi: 10.1038/s41586-019-0984-y. Epub 2019 Feb 27.

PMID:
30814737
13.

Inferring Clonal Heterogeneity in Cancer using SNP Arrays and Whole Genome Sequencing.

Zucker MR, Abruzzo LV, Herling CD, Barron LL, Keating MJ, Abrams ZB, Heerema N, Coombes KR.

Bioinformatics. 2019 Jan 24. doi: 10.1093/bioinformatics/btz057. [Epub ahead of print]

PMID:
30689715
14.

Selective stiffening of fibrin hydrogels with micron resolution via photocrosslinking.

Keating M, Lim M, Hu Q, Botvinick E.

Acta Biomater. 2019 Mar 15;87:88-96. doi: 10.1016/j.actbio.2019.01.034. Epub 2019 Jan 17.

PMID:
30660778
15.

Determining the Cause of Death Among Children Hospitalized With Respiratory Illness in Kenya: Protocol for Pediatric Respiratory Etiology Surveillance Study (PRESS).

Njuguna HN, Zaki SR, Roberts DJ, Fligner CL, Keating MK, Rogena E, Walong E, Gachii AK, Maleche-Obimbo E, Irimu G, Mathaiya J, Orata N, Lopokoiyit R, Maina J, Emukule GO, Onyango CO, Gikunju S, Owuor C, Kinuthia P, Bunei M, Fields B, Widdowson MA, Mott JA, Chaves SS.

JMIR Res Protoc. 2019 Jan 10;8(1):e10854. doi: 10.2196/10854.

16.

Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.

Alfaro CM, Pirro V, Keating MF, Hattab EM, Cooks RG, Cohen-Gadol AA.

J Neurosurg. 2019 Jan 4:1-8. doi: 10.3171/2018.8.JNS181207. [Epub ahead of print]

PMID:
30611146
17.

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.

Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ.

Blood. 2019 Mar 7;133(10):1011-1019. doi: 10.1182/blood-2018-10-879429. Epub 2018 Dec 7.

PMID:
30530801
18.

Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.

Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ.

Cancer. 2019 Feb 15;125(4):559-574. doi: 10.1002/cncr.31831. Epub 2018 Dec 3.

PMID:
30508305
19.

Outbreak of Tattoo-Associated Nontuberculous Mycobacterial Skin Infections.

Griffin I, Schmitz A, Oliver C, Pritchard S, Zhang G, Rico E, Davenport E, Llau A, Moore E, Fernandez D, Mejia-Echeverry A, Suarez J, Noya-Chaveco P, Elmir S, Jean R, Pettengill JB, Hollinger KA, Chou K, Williams-Hill D, Zaki S, Muehlenbachs A, Keating MK, Bhatnagar J, Rowlinson MC, Chiribau C, Rivera L.

Clin Infect Dis. 2018 Nov 17. doi: 10.1093/cid/ciy979. [Epub ahead of print]

PMID:
30452604
20.

The involvement of microRNA in the pathogenesis of Richter syndrome.

Van Roosbroeck K, Bayraktar R, Calin S, Bloehdorn J, Dragomir MP, Okubo K, Bertilaccio MTS, Zupo S, You MJ, Gaidano G, Rossi D, Chen SS, Chiorazzi N, Thompson PA, Ferrajoli A, Bertoni F, Stilgenbauer S, Keating MJ, Calin GA.

Haematologica. 2019 May;104(5):1004-1015. doi: 10.3324/haematol.2018.203828. Epub 2018 Nov 8.

21.

A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia.

Paul S, Jain N, Ferrajoli A, O'Brien S, Burger J, Keating M, Wierda W.

Br J Haematol. 2019 May;185(3):606-608. doi: 10.1111/bjh.15581. Epub 2018 Nov 8. No abstract available.

PMID:
30406944
22.

Toward the potential cure of leukemias in the next decade.

Kantarjian HM, Keating MJ, Freireich EJ.

Cancer. 2018 Nov 15;124(22):4301-4313. doi: 10.1002/cncr.31669. Epub 2018 Oct 6. Review. Erratum in: Cancer. 2019 May 15;125(10):1756.

PMID:
30291792
23.

Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.

Leitch HA, Buckstein R, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Shamy A, Elemary M, Wells RA.

Leuk Res. 2018 Nov;74:21-41. doi: 10.1016/j.leukres.2018.09.005. Epub 2018 Sep 19. Review.

PMID:
30286330
24.

STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells.

Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z.

Oncotarget. 2018 Sep 14;9(72):33710-33718. doi: 10.18632/oncotarget.26110. eCollection 2018 Sep 14.

25.

A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.

Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V.

Blood. 2018 Nov 22;132(21):2249-2259. doi: 10.1182/blood-2018-06-860593. Epub 2018 Sep 25.

PMID:
30254130
26.

Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?

Rozovski U, Keating MJ, Estrov Z.

Acta Haematol. 2018;140(1):51-54. doi: 10.1159/000491382. Epub 2018 Aug 16. Review.

27.

Pathology in Practice.

Edwards EE, Birch SM, Hoppes SM, Keating MK, Stoica G.

J Am Vet Med Assoc. 2018 Aug 15;253(4):423-426. doi: 10.2460/javma.253.4.423. No abstract available.

PMID:
30058964
28.

Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways.

Abruzzo LV, Herling CD, Calin GA, Oakes C, Barron LL, Banks HE, Katju V, Keating MJ, Coombes KR.

Haematologica. 2018 Dec;103(12):2069-2078. doi: 10.3324/haematol.2018.190132. Epub 2018 Jul 5.

29.

Multifocal Soft Tissue Cryptococcosis in a Renal Transplant Recipient: The Importance of Suspecting Atypical Pathogens in the Immunocompromised Host.

Ajmal S, Keating M, Wilhelm M.

Exp Clin Transplant. 2018 Jun 28. doi: 10.6002/ect.2017.0292. [Epub ahead of print]

30.

The CCC Complex COMManDs Control of LDL Cholesterol Levels.

Keating MF, Calkin AC.

Circ Res. 2018 Jun 8;122(12):1629-1631. doi: 10.1161/CIRCRESAHA.118.313074. No abstract available.

PMID:
29880494
31.

A Case of Prototheca zopfii Genotype 1 Infection in a Dog (Canis lupus familiaris).

Silveira CS, Cesar D, Keating MK, DeLeon-Carnes M, Armién AG, Luhers M, Riet-Correa F, Giannitti F.

Mycopathologia. 2018 Oct;183(5):853-858. doi: 10.1007/s11046-018-0274-5. Epub 2018 Jun 6.

PMID:
29872935
32.

Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells.

Vangapandu HV, Alston B, Morse J, Ayres ML, Wierda WG, Keating MJ, Marszalek JR, Gandhi V.

Oncotarget. 2018 May 18;9(38):24980-24991. doi: 10.18632/oncotarget.25166. eCollection 2018 May 18.

33.

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies.

Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG.

Leukemia. 2018 Nov;32(11):2388-2398. doi: 10.1038/s41375-018-0132-y. Epub 2018 Apr 17.

34.

STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells.

Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z.

Oncotarget. 2018 Apr 20;9(30):21268-21280. doi: 10.18632/oncotarget.25066. eCollection 2018 Apr 20.

35.

Recurrent and Fixed Neutrophilic Dermatosis Associated With Dasatinib.

Bergman JC, Ly TY, Keating MM, Hull PR.

J Cutan Med Surg. 2018 Nov/Dec;22(6):621-623. doi: 10.1177/1203475418775663. Epub 2018 May 13.

PMID:
29754527
36.

Prototheca zopfii Colitis in Inherited CARD9 Deficiency.

Sari S, Dalgic B, Muehlenbachs A, DeLeon-Carnes M, Goldsmith CS, Ekinci O, Jain D, Keating MK, Vilarinho S.

J Infect Dis. 2018 Jul 2;218(3):485-489. doi: 10.1093/infdis/jiy198.

PMID:
29659908
37.

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ.

Cancer. 2018 Jun 15;124(12):2534-2540. doi: 10.1002/cncr.31370. Epub 2018 Apr 12.

PMID:
29645075
38.

Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy.

Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder M.

Oncoimmunology. 2018 Jan 15;7(4):e1417720. doi: 10.1080/2162402X.2017.1417720. eCollection 2018.

39.

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ.

Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. Review.

PMID:
29540348
40.

Candida pneumonia with severe clinical course, recovery with antifungal therapy and unusual pathologic findings: A case report.

Dermawan JKT, Ghosh S, Keating MK, Gopalakrishna KV, Mukhopadhyay S.

Medicine (Baltimore). 2018 Jan;97(2):e9650. doi: 10.1097/MD.0000000000009650.

41.

Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.

Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z.

Leukemia. 2018 Oct;32(10):2278-2281. doi: 10.1038/s41375-018-0059-3. Epub 2018 Feb 20. No abstract available.

PMID:
29479067
42.

Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.

Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z.

Leuk Lymphoma. 2018 Feb 21:1-6. doi: 10.1080/10428194.2018.1439167. [Epub ahead of print]

PMID:
29465264
43.

Sprouting angiogenesis induces significant mechanical heterogeneities and ECM stiffening across length scales in fibrin hydrogels.

Juliar BA, Keating MT, Kong YP, Botvinick EL, Putnam AJ.

Biomaterials. 2018 Apr;162:99-108. doi: 10.1016/j.biomaterials.2018.02.012. Epub 2018 Feb 6.

44.

The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide.

Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K.

Front Immunol. 2018 Jan 15;8:1773. doi: 10.3389/fimmu.2017.01773. eCollection 2017.

45.

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.

Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A.

Blood. 2018 Apr 19;131(16):1820-1832. doi: 10.1182/blood-2017-11-817296. Epub 2018 Jan 22.

46.

Correction: Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy.

Lu W, Hu Y, Chen G, Chen Z, Zhang H, Wang F, Feng L, Pelicano H, Wang H, Keating MJ, Liu J, McKeehan W, Wang H, Luo Y, Huang P.

PLoS Biol. 2017 Dec 11;15(12):e1002616. doi: 10.1371/journal.pbio.1002616. eCollection 2017 Dec.

47.

The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.

Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z.

Br J Haematol. 2018 Jan;180(1):33-40. doi: 10.1111/bjh.15018. Epub 2017 Nov 21.

48.

Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.

Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, Ivan C, Morse J, Nelson M, Keating MJ, Wierda WG, Marszalek JR, Gandhi V.

Leukemia. 2018 Apr;32(4):920-930. doi: 10.1038/leu.2017.321. Epub 2017 Nov 3.

49.

Interpreting Mobile and Handheld Air Sensor Readings in Relation to Air Quality Standards and Health Effect Reference Values: Tackling the Challenges.

Woodall GM, Hoover MD, Williams R, Benedict K, Harper M, Soo JC, Jarabek AM, Stewart MJ, Brown JS, Hulla JE, Caudill M, Clements AL, Kaufman A, Parker AJ, Keating M, Balshaw D, Garrahan K, Burton L, Batka S, Limaye VS, Hakkinen PJ, Thompson B.

Atmosphere (Basel). 2017;8(10):182. doi: 10.3390/atmos8100182. Epub 2017 Sep 21.

50.

A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.

Houston BL, Jayakar J, Wells RA, Lenis M, Zhang L, Zhu N, Leitch HA, Nevill TJ, Yee KWL, Leber B, Sabloff M, St-Hilaire E, Kumar R, Geddes M, Shamy A, Storring JM, Keating MM, Elemary M, Delage R, Mamedov A, Buckstein R.

Ann Hematol. 2017 Dec;96(12):2025-2029. doi: 10.1007/s00277-017-3137-0. Epub 2017 Oct 3.

PMID:
28975386

Supplemental Content

Loading ...
Support Center